| The White House is hosting a series of virtual conversations to highlight promising areas of current research and understand what is still needed to address the nation's deepening mental health crisis. This event on July 21, 2022, featured NIMH researcher Carlos Zarate, M.D., an expert on mood disorders who spoke about work to develop new medications for treatment-resistant depression and described the arc from fundamental research to a now-approved treatment.
In 2019, FDA approved esketamine – a potent, intranasal form of ketamine – which has been shown to act almost immediately to relieve depressive symptoms in many patients with this type of treatment-resistant depression.
Dr. Zarate is Chief of the Section on the Neurobiology and Treatment of Mood Disorders and Chief of the Experimental Therapeutics and Pathophysiology Branch at NIMH, and Clinical Professor of Psychiatry and Behavioral Sciences at The George Washington University. | 
No comments:
Post a Comment